A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir(LPV/RTV), Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimen(s)

CompletadoFase 3ClinicalTrials.gov

ID: NCT00028301Tipo: INTERVENTIONALInicio: 1 de feb de 2001Fin estimado: 1 de sept de 2003

Enfermedades Infecciosas

Traducción no disponible, mostrando original

Resumen

This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.

Descripción detallada

The study is designed to determine the metabolic changes, antiviral activity, safety, and tolerability of atazanavir as compared to LPV/RTV, each in combination with 2 nucleosides, over the initial 24 weeks, with a final analysis at 48 weeks.

Elegibilidad

Edad mínima: 16 YearsSexo: ALL

Criterios de inclusión

Patients may be eligible for this study if they:
Are receiving a PI-containing highly active antiretroviral therapy (HAART) for at least 12 weeks.
Have a viral load of 1,000 or more copies/ml within 4 weeks of screening and within 4 weeks prior to randomization.
Have 2 CD4 cell counts of 50 or more cells/mm3 at least 96 hours apart and within 4 weeks before randomization.
Are at least 16 years old.
Have a documented virologic response to at least 1 HAART regimen.
Have phenotypic sensitivity to at least 2 of the following: ddl, d4T, ZDV, 3TC, ABC.
Have phenotypic sensitivity to atazanavir and LPV/RTV.
Use effective barrier methods of birth control.
Will be available for 48 weeks.

Criterios de exclusión

Patients will not be eligible for this study if they:
Have taken 2 or more PIs and had virologic failure.
Have taken atazanavir or LPV/RTV.
Have an HIV-related infection (within 30 days) or any medical condition requiring treatment at the time of enrollment.
Have had acute hepatitis in the 30 days prior to study entry.
Have received certain drugs within 3 months of study start or expect to need them at time of enrollment.
Abuse alcohol or drugs in a way that would interfere with the study.
Have very bad diarrhea within 30 days prior to study entry.
Are pregnant or breast-feeding.
Have a history of hemophilia.
Use lipid-lowering drugs (within the previous 30 days).
Have cardiomyopathy or symptoms of other heart disease.
Cannot take medicine by mouth.
Have any other condition that would interfere with the study.
Have pancreatitis, if choosing ddI as part of NRTI pair.
Have bilateral peripheral neuropathy at time of screening, if choosing ddI or or d4T as part of the NRTI pair.

Intervenciones

drug

Atazanavir

drug

Lopinavir/Ritonavir

Ubicaciones

Claudia Rodriguez MD

Buenos Aires, Argentina

Elida Pallone MD

Buenos Aires, Argentina

Fundacion Huesped

Buenos Aires, Argentina

Hospital Italiano

Buenos Aires, Argentina

CAICI

Rosario Santa Fe, Argentina

Patrocinadores

PrincipalBristol-Myers Squibb

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Randomized Open-label Study of the Antiviral Efficacy a... | EligiMed